New no-needle COVID-19 vaccine undergoing testing
Updated: 1:01 PM EDT Sep 7, 2021
Brian Hamrick
WE TEACH OUR DOGS LOTS OF TRIC.KS BUT NOW WE'RE LEARNING ONE FROM THEM AS NEW RESEARCH BEGINS ON A NEW VACNECI MADE WITH ELEMENTS MANY WHO HAVE DOGS. HAVE ALREADY BEEN AROUND IT IS COMMONLY USED IN A CANINE VACCINE THE DOCTOR PLAU SPEARMAN IS LEADINGHE T RESEARCH AT CINCINNATI CHILDREN'S HOSPITAL ON THISO N NEEDLE VACCINE. IT'S COMPLETELY DIFFERENT THAN THE MRNA IN THE SENSE THAT THIS IS A LIVE, BUT HARMLESS VIRAL VECTOR THAT THAT WE SQUIRT INTO THE NOSE. IT'S LIKE MORE TRADITIONAL NASAL VACCESIN THAT HAVE BEEN USED FOR INFLUENZA OVER THE YEARS. THIS ONE USES A LIVE VIRUS A IT HASN'T BEEN USED IN HUMANS, BUT MANY PEOPLE HAVEAD H CONTACT WITH IT. THE PIV5 VIRUS ITSELF OR PARENT FUNDS OF VIRUS TYPE 5 IS PART OF THE KENNEL COUGH VACCINE THAT'S GIVEN TO DOGS AND PEOPLE GET EXPOSED TO THAT AND WE KNOW THEY DO BECAUSE THAT'S BEEN EVALUATED AND AS FAR AS WE KWNO THEY'VE NEVER HAD SYMPTOMS BESIDES THE FACT THAT IT USES NO NEEDLES RESEARCHERS BELIEVE THE KEY ADVANTAGE IS IT BUILDS PROTECTION INHE T NASAL WHEN UPPER RESPIRATORY SYSTEM RIGHT WHERE COV? VIRUSES ATTACK SO WE ARE HOPEFUL THAT THISYP TE OF VACCINE AN INTRANASAL VACCINE MIGHT ACTUALLY PREVENT THE UPPER AIRWAY FROM GETTING INFECTED WHICH IS ALWAYS WHAT HAPPENS BEFORE YOU GET THE LOWER RESPIRATORY TRACT. THE RESEARCH IS BEING DONE AT CHILDREN'SOR F A COMPANY CALDLE SCION BACK. THE VACCINE IS CALDLE CVXGA1 IN A STUDY. IT TAKES A PAGE FROM PUPS HOPING TO UNLEASH A NEW VIRUS WATCHDOG. AND NOW WE HAVE THE INFORMATION. ON HOW TO GET INVOLVED IN THE STUDY ON OUR WEBTESI WLWT.COM. THEY'RE LOOKING FOR PEOPLE OVER THE AGES 18 TO 75. THEY ONLY NEED ABOUT 20 OF THEM FOR THIS INITIAL STUDY. BUT IF THINGS GO AS PLANNED, THEY'L' DO A BIGGER STUDY IT COULD BE AVAILABLE TO GO TO THE FDA AS SOO ANS THE MIDDLE OF NEXT YREA REPORTING LIVE. RAIN HAMRICK WLWT NEWS 5 NOW BRIAN, HOW SAFE IS THEIV LE VIRUS THAT? LOSING IN THIS VACCINE YEAH, WELL, I AS A RESEARCHERS ABOUT THAT THEY SAID BECAUSE TYHE BELIEVE SO MANY PEOPLEAVE H ALREADY BEEN EXPOSED TO THIS. THEY THINK IT'S ' HARMLESS VIRUS THAT DOES WHAT THESE VIRUSES DO IN THESERA TDITIONAL VACCINES BASICALLY EXPOSES PEOPLE TO A VISRU THAT IS HARMLESS TO TRY AND BUILD UP IMMUNITY FOR ONE. THAT'SOT N ACTUALLY. ALL RIGHT, BRIAN HAMRICK REPORTING LIVE FOR US ON THIS GROUNDBREAKING.
A new, no-needle approach to COVID-19 vaccines is being tested by researchers who are hoping it acts like a virus watchdog in the area where COVID-19 attacks."It could be a very, very innovative and new type of vaccine. So, we're really hopeful of how this could help us with the pandemic," said Cincinnati Children's Hospital Dr. Paul Spearman.Spearman is leading the research on a vaccine known as CVXGA1.The vaccine is delivered in a nasal spray, like some influenza vaccines.Researchers believe the vaccine delivered in the nose will help the protection build there and in the upper respiratory system where COVID-19 first attacks and it may do that even better than the mRNA vaccines."They do generate some antibodies in the mucosal track, but we think this one has a potential to generate a lot more," Spearman said. "The difference is, it will generate immunity, not just throughout the systemic circulation in the body but also in the mucosal areas of the nose."Like other nasal vaccines, the virus in the COVID-19 nasal version is also live. Researchers believe this virus is safe because, while it hasn't been directly tested on people, many have had contact with it."The Pi5 virus itself parainfluenza virus type 5 is part of the kennel cough vaccine that's given to dogs and people get exposed to that. We know they do because that's been evaluated and as far as we know, they've never had symptoms," Spearman said.Enrollment begins within a week or so. Researchers need 15-20 people ages 18 to 75.They need people who have not had a vaccine and have not had COVID-19.
A new, no-needle approach to COVID-19 vaccines is being tested by researchers who are hoping it acts like a virus watchdog in the area where COVID-19 attacks.
"It could be a very, very innovative and new type of vaccine. So, we're really hopeful of how this could help us with the pandemic," said Cincinnati Children's Hospital Dr. Paul Spearman.
Spearman is leading the research on a vaccine known as CVXGA1.
The vaccine is delivered in a nasal spray, like some influenza vaccines.
Researchers believe the vaccine delivered in the nose will help the protection build there and in the upper respiratory system where COVID-19 first attacks and it may do that even better than the mRNA vaccines.
"They do generate some antibodies in the mucosal track, but we think this one has a potential to generate a lot more," Spearman said. "The difference is, it will generate immunity, not just throughout the systemic circulation in the body but also in the mucosal areas of the nose."
Like other nasal vaccines, the virus in the COVID-19 nasal version is also live.
Researchers believe this virus is safe because, while it hasn't been directly tested on people, many have had contact with it.
"The Pi5 virus itself parainfluenza virus type 5 is part of the kennel cough vaccine that's given to dogs and people get exposed to that. We know they do because that's been evaluated and as far as we know, they've never had symptoms," Spearman said.
Enrollment begins within a week or so.
Researchers need 15-20 people ages 18 to 75.
They need people who have not had a vaccine and have not had COVID-19.
Why is the COVID-19 vaccine for younger children taking longer?